Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
Abstract: The present invention further provides a composition for inhibiting purine body absorption, a composition for inhibiting purine nucleotide metabolism, a composition for inhibiting phosphatase, a composition for inhibiting uric acid level elevation, a composition for improving blood pressure, a composition for improving blood glucose level, a composition for improving liver function, a composition for controlling serum iron level, or a composition for promoting calcium absorption, comprising an inositol phosphate or a salt thereof. The present invention further provides a composition comprising an inositol phosphate or a salt thereof, wherein the taste thereof is improved by adding thereto a predetermined amount of calcium lactate.
Abstract: The present invention relates to crystalline (thio)nicotinamide ribofuranoside salts, methods of making such crystalline salts, a pharmaceutical composition comprising same, and use of said crystalline salts as nutritional (dietary) supplements. Furthermore, the present invention relates to a composition comprising amorphous (thio)nicotinamide ribofuranoside salts and its use as nutritional (dietary) supplement.
Abstract: A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
September 20, 2022
Assignee:
ARC Medical Devices
Inventors:
Christopher Michael Kevin Springate, Sailesh Haresh Daswani
Abstract: The present application relates to a method for prepare a Cangrelor tetrasodium salt, comprising: using N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)sulfonyl]adenosine as a raw material to undergo two steps of reaction to obtain a reaction solution containing the Cangrelor tetrasodium salt; separating and purifying once by C18 silica gel column chromatography so as to obtain a Cangrelor tetrasodium salt pure product. The present application has the advantages of short synthesis route, mild reaction conditions, sufficient reaction, simple operation, high product yield, high purity, and environmental friendliness, and is suitable for large-scale preparation.
Type:
Grant
Filed:
December 11, 2018
Date of Patent:
September 13, 2022
Assignee:
Yabao Pharmaceutical Group Co., Ltd.
Inventors:
Fanghui Tang, Jiyu Bao, Junfeng Gao, Zhouhong Tan
Abstract: The present disclosure provides 3? protected nucleotides, including those 3? protected nucleotides having a detectable tag. Systems and methods of sequencing nucleic acids using the 3? protected nucleotides are also disclosed, such as the sequencing of a nucleic acid using a nanopore or the sequencing of a nucleic acid via sequencing-by-synthesis.
Type:
Grant
Filed:
December 16, 2019
Date of Patent:
September 13, 2022
Assignee:
ROCHE SEQUENCING SOLUTIONS, INC.
Inventors:
Frank Bergmann, Peter Crisalli, Dieter Hiendl, Omid Khakshoor, Meng Taing
Abstract: The present disclosure provides a low-molecular-weight Tremella aurantialba glucuronoxylomannan (LTAG) as well as a preparation method and an application thereof, and specifically relates to the technical field of medicine. The LTAG provided in the present disclosure has a weight-average molecular weight of 8,000-24,000 Da. In the method of preparing LTAG as provided in the present disclosure, Tremella aurantialba glucuronoxylomannan is depolymerized by peroxides so as to get low-molecular-weight products, which are then exchanged into pharmaceutically acceptable salts through cation exchange resins. The resulting LTAG has a clear structure, a low viscosity and a good solubility, has a strong immune-enhancing activity, and is capable of acting on TLR4 receptor-activated macrophagocytes and promoting the production of various immune factors, so it can be used in the prevention and/or treatment of immunodeficiency-related diseases.
Type:
Grant
Filed:
January 6, 2021
Date of Patent:
September 6, 2022
Assignee:
GUANGXI UNIVERSITY OF CHINESE MEDICINE
Inventors:
Qingxia Yuan, Longyan Zhao, Hong Li, Ziyi Wei
Abstract: The present invention relates to the cosmetic use, as moisturizer for keratin materials, preferably the skin, of one or more 5-oxazolidine-2,4-dione C-glycoside derivatives corresponding to formula (I) below, and also the solvates and/or the isomers (optical, geometric, tautomers) thereof and/or the salts thereof: (I)
Type:
Grant
Filed:
June 19, 2019
Date of Patent:
August 23, 2022
Assignee:
L'OREAL
Inventors:
Maria Dalko, Amélie Prevot-Gueguiniat, Marie-céline Frantz, Sébastien Dropsit
Abstract: Methods of producing a chitin composition by which the properties of the chitin composition derived from krill, such as molecular weight (chain length) and degree of acetylation are reproducible, are claimed. Such reproducible production methods allow for a wide use of the chitin composition end products in pharmaceutical and biomedical applications. The methods also allow for the production of chitin compositions which preserve the native state of chitin.
Abstract: High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
August 23, 2022
Assignee:
ARC Medical Devices Inc.
Inventors:
Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun
Abstract: The present invention is a process for the preparation of certain 5?-phosphoramidate nucleotide diastereoisomers. The phosphoramidates include those useful in the treatment of cancer such as NUC-3373 (5-fluoro-2?-deoxyuridine-5?-O-[1-naphthyl(benzyloxy-L-alaninyl)]phosphate).
Abstract: Provided herein are crystalline forms of nicotinamide riboside chloride and methods of making the same. Also provided are compositions comprising the crystalline form of nicotinamide riboside chloride, and therapeutic methods employing the crystalline form of nicotinamide riboside chloride.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
August 16, 2022
Assignee:
Elysium Health, Inc.
Inventors:
Eric Marcotulli, Dan Alminana, Ryan Dellinger, Mark Morris
Abstract: Novel steviol glycoside compounds characterized by a first group of four glucopyranose residues attached via the number 13 carbon (C13) of the steviol moiety and a second group of two or three glucopyranose residues attached via the number 19 carbon (C19) of the steviol moiety are described, and exemplified by compounds 1-4. These compounds can be present in a composition with other steviol glycosides (e.g., Reb D and Reb M) to enhance their solubilities. Accordingly, the novel compounds can facilitate the preparation of Compound name (C-13) aqueous compositions having a higher concentration of steviol glycosides. A steviol glycoside composition including one or more of compounds 1-4 can be used as a sweetener composition to sweeten other compositions (sweetenable compositions) such as foods, beverages, medicines, oral hygiene compositions, nutraceuticals, and the like.
Abstract: The purpose of the present invention is to provide a novel compound which has antibacterial activity against Mycobacterium avium and Mycobacterium intracellulare that are causative bacteria of MAC infection and which is different in backbone structure from known drugs for treatment of MAC infection. One aspect of the present invention relates to a compound of Formula (I) [where R1 has the same meaning as described in the specification and claims] or a salt thereof, or a solvate thereof. Another aspect of the present invention relates to a method for producing the compound of Formula (I) or a salt thereof, or a solvate thereof, and a therapeutic agent for Mycobacterium avium complex infection (MAC infection), which comprises the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient.
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
August 9, 2022
Assignees:
THE KITASATO INSTITUTE, OP BIO FACTORY CO., LTD.
Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
Type:
Grant
Filed:
September 29, 2020
Date of Patent:
August 9, 2022
Assignee:
MANDOS LLC
Inventors:
Bernardus Nicolaas Machielse, Allan Darling
Abstract: The present invention relates to a method for preparing a crystalline functional sweetener, and more specifically, relates to a method for preparing a crystalline functional sweetener for raising the crystallization yield and increasing the particle size by controlling the content of impurities or production of impurities comprised in a solution for preparing the crystal.
Type:
Grant
Filed:
February 7, 2019
Date of Patent:
August 2, 2022
Assignee:
SAMYANG CORPORATION
Inventors:
Go-Eun Kim, Jae-Kyung Yang, Kyung-Hun Ryu, Sung Won Park, Ji Won Park, Eunsoo Choi
Abstract: Provided herein are solid phase methods for the synthesis of conjugated oligomeric compounds and intermediates used in such methods. In particular, the solid phase methods provide for addition of a phosphoramidite functionalized conjugate group to a solid support bound oligomeric compound. The methods also provide an increase in overall yield and a cost benefit over existing methods.
Abstract: The present invention provides a novel process for preparing an oligosaccharide C-glycoside derivative of formula I, comprising reacting a compound of formula II with compound of formula III in the presence of at least one primary or secondary amine and at least one additive [in the formulae, the substituents are as defined herein], and novel oligosaccharide C-glycoside derivatives that can be prepared using the process.
Type:
Grant
Filed:
March 22, 2019
Date of Patent:
August 2, 2022
Assignee:
OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION
Abstract: The present invention concerns a process for the preparation and purification of the sodium salt of HA from the fermentation broth of Streptococcus or Bacillus or from rooster combs, the sodium salt of HA obtained and purified with said process and pharmaceutical, cosmetic and nutritional compositions comprising said sodium salt of HA.
Type:
Grant
Filed:
October 30, 2020
Date of Patent:
July 26, 2022
Assignee:
FIDIA FARMACEUTICI S.p.A.
Inventors:
Mara Pittarello, Francesco Borile, Vincenza Corsa